

REMARKS

This application has been amended in a manner that is believed to place it in condition for allowance at the time of the next Official Action.

Claims 27, 32-33, 44-45, 48-54 and 56-60 are pending in the present application. Claims 27, 32-33, 44-45, 48-54 and 56-60 have been amended to address the formal matters raised in the outstanding Official Action. In addition, independent claims 27, 44 and 51 have been amended to recite "A method for the treatment of Alzheimer's disease". Claim 55 has been canceled.

In the outstanding Official Action, claims 27, 32-33, 44-45 and 48-60 were rejected under 35 USC §112, first paragraph, for allegedly not satisfying the enablement requirement. However, at this time, applicant notes with appreciation the indication by the Examiner that the specification is enabling for a method of treating Alzheimer's disease.

Accordingly, independent claims 27, 44 and 51 have been amended to recite "A method for the treatment of Alzheimer's disease". Thus, while applicant does not disclose any applications or utilities for the claimed invention in this application or any future applications, the term "prevention" no longer appears in the claims.

Thus, in view of the above, applicant believes that the present amendment obviates this rejection.

Claims 27, 32-33, 44-45 and 48-60 were rejected under 35 USC §112, second paragraph, for allegedly being indefinite. Applicant believes the present amendment obviates this rejection.

In imposing the rejection, the Official Action stated that the claims were indefinite because the binding properties of the antibody were allegedly unclear. Accordingly, the Official Action suggested we amend claims 27, 44, and 51 to recite "wherein said antibody binds to said A β -Arc peptide".

However, it is respectfully submitted that this does not quite accurately reflect the nature of the present invention. Rather, the present disclosure teaches that the claimed antibodies will bind with A β -Arc and A β wild-type peptides in a protofibril state. This is supported in the present specification at page 4, lines 8-9 and page 8, lines 10-15. In addition, applicant submits herewith a declaration by Dr. Lars LANNFELT which shows that the antibody of the claimed invention binds to arctic and wild-type A β peptides in protofibril conformation. Accordingly, claims 27, 44 and 51 have been amended to reflect this.

The outstanding Official Action also rejected claims 52 and 55. While claim 55 has been canceled, claim 52 has been amended so that claim 52 is distinguishable from claim 45.

In view of the above, applicant believes that claims 27, 32-33, 44-45, 48-54 and 56-60 are definite to one skilled in the art.


At this time, applicant also notes that the specification has been amended as suggested by the Examiner. Applicant thanks Examiner Chernyshev for her suggestion.

In view of the present amendment and the foregoing remarks, therefore, applicant believes that the present application is in condition for allowance at the time of the next Official Action. Allowance and passage to issue on that basis is respectfully requested.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 25-0120 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17.

Respectfully submitted,

YOUNG & THOMPSON


Philip Dubois, Reg. No. 50,696
745 South 23rd Street
Arlington, VA 22202
Telephone (703) 521-2297
Telefax (703) 685-0573
(703) 979-4709

PD/lrs

APPENDIX:

The Appendix includes the following item:

- Declaration Under Rule 132 by Dr. Lars LANNFELT